FindTrial
Sign In

sevoflurane reduce degradation of Glycocalyx mediated by cardiopulmonary bypass operation

sevoflurane reduce degradation of Glycocalyx mediated by cardiopulmonary bypass operation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016367
Enrollment
Unknown
Registered
2018-05-28
Start date
2018-06-10
Completion date
Unknown
Last updated
2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart disease

Interventions

Sevoflurane group:Sevoflurane
propofol group:propofol

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: patient with mitral valve replacement or aortic valve replacement

Exclusion criteria

Exclusion criteria: A history of cardiac surgery, combined surgery (simultaneous valvuloplasty and aneurysm), severe aortic stenosis (valvular area 150U), renal insufficiency (creatinine> 1.5 mg/dl), chronic obstructive pulmonary disease Expiratory volume less than 0.8L), neurological history, severe stenosis, severe infection (calcitonin> 0.5ug/L, CRP> 8.5), diabetes.

Design outcomes

Primary

MeasureTime frame
Glycocalyx;—

Secondary

MeasureTime frame
urinary albumin/creatinine;—

Countries

China

Contacts

Public ContactWeijian Wang

The First Affiliated Hospital of Wenzhou Medical University

wangwj2002@163.com+86 13806683232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 16, 2026